Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

References

• Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-5; PMID:11951032; https://doi.org/10.1126/science.1071059
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; https://doi.org/10.1038/nm.3708
   PubMed Web of Science ®Google Scholar
• Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202:8-32; PMID:15546383; https://doi.org/10.1111/j.0105-2896.2004.00204.x
   PubMed Web of Science ®Google Scholar
• van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006; 25:361-72; PMID:16979568; https://doi.org/10.1016/j.immuni.2006.08.014
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140:805-20; PMID:20303872; https://doi.org/10.1016/j.cell.2010.01.022
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 2014; 32:513-45; PMID:24555472; https://doi.org/10.1146/annurev-immunol-032713-120231
   PubMed Web of Science ®Google Scholar
• Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15:563-91; PMID:9143700; https://doi.org/10.1146/annurev.immunol.15.1.563
   PubMed Web of Science ®Google Scholar
• Lazear HM, Nice TJ, Diamond MS. Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity 2015; 43:15-28; PMID:26200010; https://doi.org/10.1016/j.immuni.2015.07.001
   PubMed Web of Science ®Google Scholar
• O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-lambda4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res 2014; 34:829-38; PMID:24786669; https://doi.org/10.1089/jir.2013.0136
   PubMed Web of Science ®Google Scholar
• Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30:16-34; PMID:21235323; https://doi.org/10.3109/08830185.2010.529976
   PubMed Web of Science ®Google Scholar
• Beutler BA. TLRs and innate immunity. Blood 2009; 113:1399-407; PMID:18757776; https://doi.org/10.1182/blood-2008-07-019307
   PubMed Web of Science ®Google Scholar
• Lee SM, Kok KH, Jaume M, Cheung TK, Yip TF, Lai JC, Guan Y, Webster RG, Jin DY, Peiris JS. Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci U S A 2014; 111:3793-8; PMID:24567377; https://doi.org/10.1073/pnas.1324266111
   PubMed Web of Science ®Google Scholar
• Oosting M, Cheng SC, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, Arts P, Garritsen A, van Eenennaam H, Sturm P et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci U S A 2014; 111:E4478-84; PMID:25288745; https://doi.org/10.1073/pnas.1410293111
   PubMed Web of Science ®Google Scholar
• O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7:353-64; PMID:17457343; https://doi.org/10.1038/nri2079
   PubMed Web of Science ®Google Scholar
• Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 1998; 441:106-10; PMID:9877175; https://doi.org/10.1016/S0014-5793(98)01514-2
   PubMed Web of Science ®Google Scholar
• Loo YM, Gale M, Jr. Immune signaling by RIG-I-like receptors. Immunity 2011; 34:680-92; PMID:21616437; https://doi.org/10.1016/j.immuni.2011.05.003
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale M Jr, Akira S et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175:2851-8; PMID:16116171; https://doi.org/10.4049/jimmunol.175.5.2851
   PubMed Web of Science ®Google Scholar
• Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005; 122:669-82; PMID:16125763; https://doi.org/10.1016/j.cell.2005.08.012
   PubMed Web of Science ®Google Scholar
• Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6:981-8; PMID:16127453; https://doi.org/10.1038/ni1243
   PubMed Web of Science ®Google Scholar
• Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19:727-40; PMID:16153868; https://doi.org/10.1016/j.molcel.2005.08.014
   PubMed Web of Science ®Google Scholar
• Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437:1167-72; PMID:16177806; https://doi.org/10.1038/nature04193
   PubMed Web of Science ®Google Scholar
• Ting JP, Willingham SB, Bergstralh DT. NLRs at the intersection of cell death and immunity. Nat Rev Immunol 2008; 8:372-9; PMID:18362948; https://doi.org/10.1038/nri2296
   PubMed Web of Science ®Google Scholar
• Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009; 10:1073-80; PMID:19701189; https://doi.org/10.1038/ni.1782
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol 2012; 12:813-20; PMID:23175229; https://doi.org/10.1038/nri3339
   PubMed Web of Science ®Google Scholar
• Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006; 126:659-62; PMID:16923387; https://doi.org/10.1016/j.cell.2006.08.002
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5; PMID:11130078; https://doi.org/10.1038/35047123
   PubMed Web of Science ®Google Scholar
• Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, Takeshita F, Ludwig H, Sutter G, Suzuki K, Hemmi H et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7:40-8; PMID:16286919; https://doi.org/10.1038/ni1282
   PubMed Web of Science ®Google Scholar
• Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448:501-5; PMID:17618271; https://doi.org/10.1038/nature06013
   PubMed Web of Science ®Google Scholar
• Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009; 138:576-91; PMID:19631370; https://doi.org/10.1016/j.cell.2009.06.015
   PubMed Web of Science ®Google Scholar
• Corrales L, McWhirter SM, Dubensky TW, Jr., Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest 2016; 126:2404-11; PMID:27367184; https://doi.org/10.1172/JCI86892
   PubMed Web of Science ®Google Scholar
• Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013; 339:786-91; PMID:23258413; https://doi.org/10.1126/science.1232458
   PubMed Web of Science ®Google Scholar
• Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, Lienenklaus S, Nilsson LM, Kröger A, Nilsson JA et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 2015; 42:332-43; PMID:25692705; https://doi.org/10.1016/j.immuni.2015.01.012
   PubMed Web of Science ®Google Scholar
• White MJ, McArthur K, Metcalf D, Lane RM, Cambier JC, Herold MJ, van Delft MF, Bedoui S, Lessene G, Ritchie ME et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 2014; 159:1549-62; PMID:25525874; https://doi.org/10.1016/j.cell.2014.11.036
   PubMed Web of Science ®Google Scholar
• Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134:587-98; PMID:18724932; https://doi.org/10.1016/j.cell.2008.06.032
   PubMed Web of Science ®Google Scholar
• Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458:509-13; PMID:19158676; https://doi.org/10.1038/nature07710
   PubMed Web of Science ®Google Scholar
• Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, Sirois CM, Jin T, Latz E, Xiao TS et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010; 11:997-1004; PMID:20890285; https://doi.org/10.1038/ni.1932
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu YJ. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol 2011; 12:959-65; PMID:21892174; https://doi.org/10.1038/ni.2091
   PubMed Web of Science ®Google Scholar
• Hamilton JA, Whitty GA, Kola I, Hertzog PJ. Endogenous IFN-alpha beta suppresses colony-stimulating factor (CSF)-1-stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-alpha. J Immunol 1996; 156:2553-7; PMID:8786318
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002; 416:744-9; PMID:11961557; https://doi.org/10.1038/416744a
   PubMed Web of Science ®Google Scholar
• Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA, De Weerd N, Roisman LC, Rossjohn J, Robertson SA et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 2013; 339:1088-92; PMID:23449591; https://doi.org/10.1126/science.1233321
   PubMed Web of Science ®Google Scholar
• Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, Sen GC, Komarova EA, Gudkov AV. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A 2013; 110:E89-98; PMID:23236145; https://doi.org/10.1073/pnas.1216922110
   PubMed Web of Science ®Google Scholar
• Uze G, Schreiber G, Piehler J, Pellegrini S. The receptor of the type I interferon family. Curr Top Microbiol Immunol 2007; 316:71-95; PMID:17969444
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014; 14:36-49; PMID:24362405; https://doi.org/10.1038/nri3581
   PubMed Web of Science ®Google Scholar
• Khoo JJ, Forster S, Mansell A. Toll-like receptors as interferon-regulated genes and their role in disease. J Interferon Cytokine Res 2011; 31:13-25; PMID:21198355; https://doi.org/10.1089/jir.2010.0095
   PubMed Web of Science ®Google Scholar
• Piganis RA, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, Hertzog PJ. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 2011; 286:33811-8; PMID:21757742; https://doi.org/10.1074/jbc.M111.270207
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294:1540-3; PMID:11711679; https://doi.org/10.1126/science.1064890
   PubMed Web of Science ®Google Scholar
• Gresser I, Maury C, Bandu MT, Foiret D, Trojan J, Uriel J. Inhibitory effect of mouse interferon on the growth of an embryonal carcinoma in mice. J Interferon Res 1984; 4:375-81; PMID:6208297; https://doi.org/10.1089/jir.1984.4.375
   PubMedGoogle Scholar
• Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grandér D. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002; 21:1251-62; PMID:11850845; https://doi.org/10.1038/sj.onc.1205179
   PubMed Web of Science ®Google Scholar
• Jensen KE, Neal AL, Owens RE, Warren J. Interferon responses of chick embryo fibroblasts to nucleic acids and related compounds. Nature 1963; 200:433-4; PMID:14076723; https://doi.org/10.1038/200433a0
   PubMed Web of Science ®Google Scholar
• Lindahl P, Leary P, Gresser I. Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proc Natl Acad Sci U S A 1973; 70:2785-8; PMID:4517933; https://doi.org/10.1073/pnas.70.10.2785
   PubMed Web of Science ®Google Scholar
• Kudryavets YI, Bezdenezhnykh NO, Lykhova OO, Semesiuk NI, Vorontsova AL. The role of interferon as a modifier of epithelial-mesenchymal transition in tumor cells. Exp Oncol 2011; 33:178-81; PMID:21956475
   PubMedGoogle Scholar
• Balkwill F, Watling D, Taylor-Papadimitriou J. Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast. Int J Cancer 1978; 22:258-65; PMID:700890; https://doi.org/10.1002/ijc.2910220307
   PubMed Web of Science ®Google Scholar
• Hobeika AC, Subramaniam PS, Johnson HM. IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 1997; 14:1165-70; PMID:9121765; https://doi.org/10.1038/sj.onc.1200939
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Tani K, Asano S. Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages. Oncogene 1998; 16:2075-86; PMID:9572488; https://doi.org/10.1038/sj.onc.1201745
   PubMed Web of Science ®Google Scholar
• Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest. Front Biosci 2000; 5:D479-87; PMID:10762599; https://doi.org/10.2741/Sangfelt
   PubMed Web of Science ®Google Scholar
• Katayama T, Nakanishi K, Nishihara H, Kamiyama N, Nakagawa T, Kamiyama T, Iseki K, Tanaka S, Todo S. Type I interferon prolongs cell cycle progression via p21WAF1/CIP1 induction in human colon cancer cells. Int J Oncol 2007; 31:613-20; PMID:17671689; https://doi.org/10.3892/ijo.31.3.613
   PubMed Web of Science ®Google Scholar
• Einat M, Resnitzky D, Kimchi A. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest. Nature 1985; 313:597-600; PMID:3881681; https://doi.org/10.1038/313597a0
   PubMed Web of Science ®Google Scholar
• Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, Mascarenhas J, Xu M, Hoffman R. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 2010; 38:472-80; PMID:20303384; https://doi.org/10.1016/j.exphem.2010.03.005
   PubMed Web of Science ®Google Scholar
• Sangfelt Strander H. Apoptosis and cell growth inhibition as antitumor effector functions of interferons. Med Oncol 2001; 18:3-14; PMID:11778967; https://doi.org/10.1385/MO:18:1:3
   PubMed Web of Science ®Google Scholar
• Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol 1994; 88:268-74; PMID:7803269; https://doi.org/10.1111/j.1365-2141.1994.tb05017.x
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49; PMID:12766484; https://doi.org/10.1023/A:1023668705040
   PubMed Web of Science ®Google Scholar
• Lanza L, Peirano L, Bosco O, Contini P, Filaci G, Setti M, Puppo F, Indiveri F, Scudeletti M. Interferons up-regulate with different potency HLA class I antigen expression in M14 human melanoma cell line. Possible interaction with glucocorticoid hormones. Cancer Immunol Immunother 1995; 41:23-8; PMID:7543821; https://doi.org/10.1007/BF01788956
   PubMed Web of Science ®Google Scholar
• Giacomini P, Fraioli R, Nistico P, Tecce R, Nicotra MR, Di Filippo F, Fisher PB, Natali PG. Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. Int J Cancer 1990; 46:539-45; PMID:2118485; https://doi.org/10.1002/ijc.2910460334
   PubMed Web of Science ®Google Scholar
• Dunn IS, Haggerty TJ, Kono M, Durda PJ, Butera D, Macdonald DB, Benson EM, Rose LB, Kurnick JT. Enhancement of human melanoma antigen expression by IFN-beta. J Immunol 2007; 179:2134-42; PMID:17675472; https://doi.org/10.4049/jimmunol.179.4.2134
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell 2016; 166:21-45; PMID:27368099; https://doi.org/10.1016/j.cell.2016.06.028
   PubMed Web of Science ®Google Scholar
• Li S, Xie Y, Zhang W, Gao J, Wang M, Zheng G, Yin X, Xia H, Tao X. Interferon alpha-inducible protein 27 promotes epithelial-mesenchymal transition and induces ovarian tumorigenicity and stemness. J Surg Res 2015; 193:255-64; PMID:25103640; https://doi.org/10.1016/j.jss.2014.06.055
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5:275-84; PMID:15803154; https://doi.org/10.1038/nrc1590
   PubMed Web of Science ®Google Scholar
• Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S et al. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut 2017; PMID:28389531; https://doi.org/10.1136/gutjnl-2016-312623
   PubMed Web of Science ®Google Scholar
• Zhu Y, Karakhanova S, Huang X, Deng SP, Werner J, Bazhin AV. Influence of interferon-alpha on the expression of the cancer stem cell markers in pancreatic carcinoma cells. Exp Cell Res 2014; 324:146-56; PMID:24726912; https://doi.org/10.1016/j.yexcr.2014.03.020
   PubMed Web of Science ®Google Scholar
• Lee J, Sayed N, Hunter A, Au KF, Wong WH, Mocarski ES, Pera RR, Yakubov E, Cooke JP. Activation of innate immunity is required for efficient nuclear reprogramming. Cell 2012; 151:547-58; PMID:23101625; https://doi.org/10.1016/j.cell.2012.09.034
   PubMed Web of Science ®Google Scholar
• Jia D, Yang W, Li L, Liu H, Tan Y, Ooi S, Chi L, Filion LG, Figeys D, Wang L. beta-Catenin and NF-kappaB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer. Cell Death Differ 2015; 22:298-310; PMID:25257174; https://doi.org/10.1038/cdd.2014.145
   PubMed Web of Science ®Google Scholar
• Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458:904-8; PMID:19212321; https://doi.org/10.1038/nature07815
   PubMed Web of Science ®Google Scholar
• Tasdogan A, Kumar S, Allies G, Bausinger J, Beckel F, Hofemeister H, Mulaw M, Madan V, Scharfetter-Kochanek K, Feuring-Buske M et al. DNA damage-induced HSPC malfunction depends on ROS accumulation downstream of IFN-1 signaling and bid mobilization. Cell Stem Cell 2016; 19:752-67; PMID:27641306; https://doi.org/10.1016/j.stem.2016.08.007
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 2014; 25:37-48; PMID:24434209; https://doi.org/10.1016/j.ccr.2013.12.004
   PubMed Web of Science ®Google Scholar
• Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56:739-45; PMID:17195077; https://doi.org/10.1007/s00262-006-0272-1
   PubMed Web of Science ®Google Scholar
• Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood 2016; 127:1449-58; PMID:26712908; https://doi.org/10.1182/blood-2015-06-652503
   PubMed Web of Science ®Google Scholar
• Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 2016; 16:131-44; PMID:26911188; https://doi.org/10.1038/nrc.2016.14
   PubMed Web of Science ®Google Scholar
• Indraccolo S. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity 2010; 43:244-7; PMID:20166871; https://doi.org/10.3109/08916930903510963
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; https://doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6:722-9; PMID:15951814; https://doi.org/10.1038/ni1213
   PubMed Web of Science ®Google Scholar
• Gresser I, Maury C, Brouty-Boye D. Mechanism of the antitumour effect of interferon in mice. Nature 1972; 239:167-8; PMID:4561966; https://doi.org/10.1038/239167a0
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Proietti E, Santodonato L, Gabriele L, Peretti M, Plavec I, Meyer F, Kaido T, Gresser I, Belardelli F. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res 1993; 53:1107-12; PMID:8439955
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, Peretti E, Lollini PL, Nanni P, Forni G et al. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994; 153:4604-15; PMID:7963533
   PubMedGoogle Scholar
• Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14:461-70; PMID:11336691; https://doi.org/10.1016/S1074-7613(01)00126-1
   PubMed Web of Science ®Google Scholar
• Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191:1777-88; PMID:10811870; https://doi.org/10.1084/jem.191.10.1777
   PubMed Web of Science ®Google Scholar
• Mattner J, Wandersee-Steinhauser A, Pahl A, Rollinghoff M, Majeau GR, Hochman PS, Bogdan C. Protection against progressive leishmaniasis by IFN-beta. J Immunol 2004; 172:7574-82; PMID:15187137; https://doi.org/10.4049/jimmunol.172.12.7574
   PubMed Web of Science ®Google Scholar
• Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G. Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol 2011; 186:5142-50; PMID:21441457; https://doi.org/10.4049/jimmunol.1004163
   PubMed Web of Science ®Google Scholar
• Eisenthal A, Cameron RB, Rosenberg SA. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 1990; 144:4463-71; PMID:2111349
   PubMed Web of Science ®Google Scholar
• Tough DF. Modulation of T-cell function by type I interferon. Immunol Cell Biol 2012; 90:492-7; PMID:22391814; https://doi.org/10.1038/icb.2012.7
   PubMed Web of Science ®Google Scholar
• Boudreau JE, Stephenson KB, Wang F, Ashkar AA, Mossman KL, Lenz LL, Rosenthal KL, Bramson JL, Lichty BD, Wan Y. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res 2011; 71:2497-506; PMID:21307131; https://doi.org/10.1158/0008-5472.CAN-10-3025
   PubMed Web of Science ®Google Scholar
• O'Neill LA, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med 2016; 213:15-23; PMID:26694970; https://doi.org/10.1084/jem.20151570
   PubMed Web of Science ®Google Scholar
• York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, Gray EE, Zhen A, Wu NC, Yamada DH et al. Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling. Cell 2015; 163:1716-29; PMID:26686653; https://doi.org/10.1016/j.cell.2015.11.045
   PubMed Web of Science ®Google Scholar
• Wu D, Sanin DE, Everts B, Chen Q, Qiu J, Buck MD, Patterson A, Smith AM, Chang CH, Liu Z et al. Type 1 interferons induce changes in core metabolism that are critical for immune function. Immunity 2016; 44:1325-36; PMID:27332732; https://doi.org/10.1016/j.immuni.2016.06.006
   PubMed Web of Science ®Google Scholar
• Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 2016; 30:147-60; PMID:27411589; https://doi.org/10.1016/j.ccell.2016.05.016
   PubMed Web of Science ®Google Scholar
• Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E, Itri L, Gutterman JU. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986; 68:493-7; PMID:3730612
   PubMed Web of Science ®Google Scholar
• Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Gutterman JU. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986; 67:275-8; PMID:3942826
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1084-6; PMID:11287980; https://doi.org/10.1056/NEJM200104053441409
   PubMed Web of Science ®Google Scholar
• Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6:975-90; PMID:18049472; https://doi.org/10.1038/nrd2422
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-90; PMID:16339096; https://doi.org/10.1056/NEJMra043172
   PubMed Web of Science ®Google Scholar
• Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012; PMID:15342808; https://doi.org/10.1056/NEJMra041245
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405-14; PMID:26027717; https://doi.org/10.1038/nri3845
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015; 28:690-714; PMID:26678337; https://doi.org/10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 2015; 350:972-8; PMID:26516201; https://doi.org/10.1126/science.aad0779
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; https://doi.org/10.1158/0008-5472.CAN-10-2788
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024-30; PMID:10706870
   PubMed Web of Science ®Google Scholar
• Moschella F, Torelli GF, Valentini M, Urbani F, Buccione C, Petrucci MT, Natalino F, Belardelli F, Foà R, Proietti E et al. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. Clin Cancer Res 2013; 19:4249-61; PMID:23759676; https://doi.org/10.1158/1078-0432.CCR-12-3666
   PubMed Web of Science ®Google Scholar
• Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 2014; 63:259-71; PMID:24357146; https://doi.org/10.1007/s00262-013-1506-7
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T et al. STING-dependent cytosolic DNA sensing promotes radiation-induced Type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014; 41:843-52; PMID:25517616; https://doi.org/10.1016/j.immuni.2014.10.019
   PubMed Web of Science ®Google Scholar
• Twyman-Saint\sVictor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520:373-7; PMID:25754329; https://doi.org/10.1038/nature14292
   PubMed Web of Science ®Google Scholar